Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Xenon Pharmaceuticals (Nasdaq: XENE) has announced equity inducement grants to six new non-officer employees, consisting of 24,200 share options. The options were granted with an exercise price of $30.54 per common share, matching the closing price on July 31, 2025.
The share options feature a four-year vesting schedule, with 25% vesting after one year and the remaining vesting monthly over three years. Each option has a 10-year term and is subject to the company's 2025 Inducement Equity Incentive Plan.
Xenon Pharmaceuticals (Nasdaq: XENE) ha annunciato concessioni di incentivi azionari a sei nuovi dipendenti non dirigenti, per un totale di 24.200 opzioni su azioni. Le opzioni sono state assegnate con un prezzo di esercizio di 30,54 $ per azione ordinaria, corrispondente al prezzo di chiusura del 31 luglio 2025.
Le opzioni prevedono un piano di maturazione quadriennale, con il 25% che matura dopo un anno e il restante che matura mensilmente nei successivi tre anni. Ogni opzione ha una durata di 10 anni ed 猫 soggetta al Piano di Incentivi Azionari 2025 della societ脿.
Xenon Pharmaceuticals (Nasdaq: XENE) ha anunciado concesiones de incentivos en acciones para seis nuevos empleados no ejecutivos, que consisten en 24.200 opciones sobre acciones. Las opciones se otorgaron con un precio de ejercicio de 30,54 $ por acci贸n com煤n, igualando el precio de cierre del 31 de julio de 2025.
Las opciones cuentan con un programa de adquisici贸n de derechos de cuatro a帽os, con un 25 % que se adquiere despu茅s de un a帽o y el resto que se adquiere mensualmente durante los siguientes tres a帽os. Cada opci贸n tiene un plazo de 10 a帽os y est谩 sujeta al Plan de Incentivos de Capital de Inducci贸n 2025 de la empresa.
Xenon Pharmaceuticals (雮橃姢雼�: XENE)电� 6氇呾潣 鞁犼窚 牍勳瀯鞗� 歆侅洂鞐愱矊 24,200欤� 鞓奠厴 順曧儨鞚� 欤检嫕 鞙犾澑 氤挫儊鞚� 氚滍憸頄堨姷雼堧嫟. 鞚� 鞓奠厴鞚� 2025雲� 7鞗� 31鞚� 膦呹皜鞚� 欤茧嫻 30.54雼煬鞚� 頄夓偓臧�瓴╈溂搿� 攵�鞐悩鞐堨姷雼堧嫟.
欤检嫕 鞓奠厴鞚� 4雲勱皠鞚� 氩犾姢韺� 鞚检爼鞚� 臧�歆�氅�, 1雲� 頉� 25%臧� 氩犾姢韺呺悩瓿� 雮橂ǜ歆�电� 3雲� 霃欖晥 毵れ洈 氩犾姢韺呺惄雼堧嫟. 臧� 鞓奠厴鞚� 10雲� 毵岅赴鞚措┌ 須岇偓鞚� 2025雲� 鞙犾澑 欤检嫕 鞚胳劶韹半笇 瓿勴殟鞐� 霐半澕 鞝侅毄霅╇媹雼�.
Xenon Pharmaceuticals (Nasdaq : XENE) a annonc茅 des attributions d'incitations en actions 脿 six nouveaux employ茅s non cadres, comprenant 24 200 options d'achat d'actions. Les options ont 茅t茅 attribu茅es avec un prix d'exercice de 30,54 $ par action ordinaire, correspondant au cours de cl么ture du 31 juillet 2025.
Les options d'achat d'actions suivent un calendrier d'acquisition de droits sur quatre ans, avec 25 % acquis apr猫s un an et le reste acquis mensuellement sur les trois ann茅es suivantes. Chaque option a une dur茅e de 10 ans et est soumise au Plan d'incitation en actions 2025 de la soci茅t茅.
Xenon Pharmaceuticals (Nasdaq: XENE) hat Aktienanreiz-Zuteilungen an sechs neue Nicht-F眉hrungskr盲fte bekannt gegeben, bestehend aus 24.200 Aktienoptionen. Die Optionen wurden zu einem Aus眉bungspreis von 30,54 $ pro Stammaktie gew盲hrt, entsprechend dem Schlusskurs vom 31. Juli 2025.
Die Aktienoptionen unterliegen einem vierj盲hrigen Vesting-Zeitplan, wobei 25 % nach einem Jahr freigegeben werden und der Rest monatlich 眉ber drei Jahre verteilt vestet. Jede Option hat eine Laufzeit von 10 Jahren und unterliegt dem Aktienanreizplan 2025 des Unternehmens.
- None.
- None.
VANCOUVER, British Columbia and BOSTON, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced equity inducement grants to six new non-officer employees consisting of an aggregate of 24,200 share options. All of the foregoing share options were approved by the Compensation Committee of the Company鈥檚 Board of Directors with an effective date of聽July 31, 2025聽and were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
The share options have an exercise price of聽
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics. We are advancing an ion channel product portfolio to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. For more information, please visit .
鈥淴enon鈥� and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.
Contacts:
For Investors:
Chad Fugere
Vice President, Investor Relations
(857) 675-7275
For Media:
Colleen Alabiso
Senior Vice President, Corporate Affairs
(617) 671-9238
FAQ
What are the details of Xenon Pharmaceuticals' (XENE) latest equity inducement grants?
What is the vesting schedule for XENE's July 2025 inducement grants?
What is Xenon Pharmaceuticals' (XENE) main business focus?
What is the exercise price for XENE's July 2025 inducement grants?
